Article

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting System

2023-06-09

Abstract excerpt

<title>Abstract</title><p><bold>Background</bold>With the increased use of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in cancer patients, adverse events (AEs) have garnered considerable interest. We conducted this pharmacovigilance study by using the Food and Drug Administration Adverse Event Reporting System (FAERS) database to evaluated the AEs of BCR-ABL1 TKIs in cancer patients.<bold>Methods</bold>We used Open...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 99651041-286a-5c17-971d-116811dbb339
DOI: 10.21203/rs.3.rs-3031450/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemDOI 10.21203/rs.3.rs-3031450/v1Read

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for OsimertinibSemantic proximity Read

Adverse Event Profiles of CDK4/6 inhibitors: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Cross-Database Analysis of Fruquintinib-Associated adverse events: Insights from FAERS and VigiAccess databasesSemantic proximity Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

A Real-World Pharmacovigilance Study of Ceftazidime/avibactam: Data Mining of the FDA Adverse Event Reporting System (FAERS) DatabaseSemantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read

Adverse event profile differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: a real-world, pharmacovigilance studySemantic proximity Read

Signal Mining for Non-Bleeding Adverse Event in Novel Oral Anticoagulants: A Pharmacovigilance Study Based on the FAERS DatabaseSemantic proximity Read

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read

Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study.Semantic proximity Read